» Articles » PMID: 17619911

Measuring Health-related Quality of Life and Neutropenia-specific Concerns Among Older Adults Undergoing Chemotherapy: Validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N)

Overview
Specialties Critical Care
Oncology
Date 2007 Jul 11
PMID 17619911
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The present study established the psychometric properties of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N), a self-report instrument to assess neutropenia-specific concerns and health-related quality of life (HRQL), in a sample of adults 65 years of age and older.

Materials And Methods: Participants were undergoing chemotherapy for lung, breast, or ovarian cancer or non-Hodgkin's lymphoma (n = 852) and were randomly assigned to receive pegfilgrastim beginning with cycle 1 (primary prophylaxis) or pegfilgrastim subsequent to cycle 1 at their clinicians' discretion (usual care). Participants completed a self-report assessment on day 1 of each cycle (up to six cycles) and at the expected nadir of the white blood cell count of each cycle. Using factor analysis, three subscales were identified in the 19-item FACT-N subscale: Malaise, Worry, and Flu-like symptoms.

Results And Discussions: The FACT-N and each of the subscales were sensitive to the presence of neutropenia although did not correlate with the absolute neutrophil count (ANC). While ANC is a marker of the impact of chemotherapy on the myeloid precursors of the bone marrow and is correlated with risk of febrile neutropenia, however the constellation of symptoms and patient experience vary throughout the period of neutropenia as the ANC first declines and then recovers. The 19-item neutropenia subscale can be used alone; however, evidence supporting reliability and validity was most robust for aggregate scores from the FACT-N and the Trial Outcome Index-Neutropenia (TOI-N).

Conclusion: Understanding the impact of neutropenia on HRQL through the availability of a validated self-report measure will, ideally, lead to interventions to reduce the burden associated with cancer and its treatments.

Citing Articles

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation.

Elazzazy S, Al-Ziftawi N, Ibrahim M, Bujassoum S, Hamad A Front Oncol. 2024; 14:1413676.

PMID: 39114308 PMC: 11303311. DOI: 10.3389/fonc.2024.1413676.


The impact of myelosuppression on quality of life of patients treated with chemotherapy.

Crawford J, Herndon D, Gmitter K, Weiss J Future Oncol. 2024; 20(21):1515-1530.

PMID: 38587388 PMC: 11441072. DOI: 10.2217/fon-2023-0513.


A pilot study of the mistletoe and breast cancer (MAB) trial: a protocol for a randomised double-blind controlled trial.

Bryant S, Duncan L, Feder G, Huntley A Pilot Feasibility Stud. 2022; 8(1):78.

PMID: 35387677 PMC: 8985298. DOI: 10.1186/s40814-022-01036-w.


Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins M J Natl Cancer Inst. 2021; 113(10):1369-1378.

PMID: 33729494 PMC: 8486331. DOI: 10.1093/jnci/djab034.


Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.

Link H, Illerhaus G, Martens U, Salar A, Depenbusch R, Kohler A Support Care Cancer. 2020; 29(5):2519-2527.

PMID: 32944800 PMC: 7981320. DOI: 10.1007/s00520-020-05711-7.


References
1.
Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

2.
Cella D, Tulsky D, Gray G, Sarafian B, Linn E, Bonomi A . The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11(3):570-9. DOI: 10.1200/JCO.1993.11.3.570. View

3.
Balducci L, Extermann M . Management of cancer in the older person: a practical approach. Oncologist. 2000; 5(3):224-37. DOI: 10.1634/theoncologist.5-3-224. View

4.
Fortner B, Schwartzberg L, Tauer K, Houts A, Hackett J, Stolshek B . Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer. 2005; 13(7):522-8. DOI: 10.1007/s00520-004-0757-4. View

5.
Cattell R . The Scree Test For The Number Of Factors. Multivariate Behav Res. 2016; 1(2):245-76. DOI: 10.1207/s15327906mbr0102_10. View